seekingalpha.com
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Amphastar Pharmaceuticals, Inc.AMPHNASDAQ
Loading
Latest News
seekingalpha.com
Amphastar Pharmaceuticals: Why I Like Bull Put Options Strategy Here
Amphastar Pharmaceuticals (AMPH) is rated a Buy, with ~81% upside to a $33 fair value, despite margin pressures for 2026. AMPH faces declining sales in legacy products but expects mid- to high-single-digit revenue growth in 2026, led by Baqsimi and new launches. I estimate operating margin to dip to 22% in 2026 due to increased expenses, recovering to 26% by 2030 as higher-margin pipeline products ramp up.
defenseworld.net
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 12-Month Low – Here’s Why
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) shares reached a new 52-week low during mid-day trading on Friday. The stock traded as low as $19.54 and last traded at $20.44, with a volume of 726331 shares. The stock had previously closed at $19.96. Analysts Set New Price Targets AMPH has been the topic
seekingalpha.com
Amphastar: Higher Costs, Lower Growth, And A 'Value Trap' Label
Amphastar Pharmaceuticals remains a 'Hold' as growth and margin headwinds persist amid its transition from generics to a proprietary pipeline. AMPH's legacy generics are declining, branded products face growth deceleration, and margins are pressured by product mix and rising R&D/SG&A costs. FY26 revenue guidance was cut to mid- to high-single-digit growth; AMP-007's contribution is uncertain, and preclinical pipeline catalysts are years away.
defenseworld.net
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Down Following Analyst Downgrade
Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) gapped down prior to trading on Friday after Wells Fargo and Company lowered their price target on the stock from $34.00 to $30.00. The stock had previously closed at $26.49, but opened at $22.44. Wells Fargo and Company currently has an overweight rating on the
zacks.com
Compared to Estimates, Amphastar (AMPH) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
seekingalpha.com
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2025 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2025 Earnings Call Transcript
zacks.com
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.92 per share a year ago.
accessnewswire.com
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025
Net revenues of $183.1 million and $719.9 million, respectively, for the three months and fiscal year ended December 31, 2025 GAAP net income of $24.4 million, or $0.51 per share and $98.1 million, or $2.03 per share, respectively, for the fourth quarter and fiscal year Adjusted non-GAAP net income of $34.2 million, or $0.73 per share and $156.6 million, or $3.25 per share, respectively, for the fourth quarter and fiscal year Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Newswire / February 26, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months and full year ended December 31, 2025.
accessnewswire.com
Amphastar Announces FDA Approval for Ipratropium Bromide HFA
RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Ipratropium Bromide HFA Inhalation Aerosol 17mcg/actuation. The FDA determined that Amphastar's Ipratropium Bromide HFA Inhalation Aerosol is bioequivalent and therapeutically equivalent to Boehringer Ingelheim's Atrovent® HFA Inhalation Aerosol.
accessnewswire.com
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026
RANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2025 ended December 31, 2025, after the market closes on Thursday, February 26, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
defenseworld.net
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives $31.00 Consensus Target Price from Analysts
Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) have been assigned a consensus recommendation of "Hold" from the eight research firms that are currently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month
defenseworld.net
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives $31.00 Consensus Price Target from Analysts
Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) have received a consensus rating of "Hold" from the eight ratings firms that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12-month
seekingalpha.com
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
accessnewswire.com
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound
Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA / ACCESS Newswire / January 12, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that it has entered into an exclusive license agreement (the "Agreement") with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. ("Hanxin") for the development, and commercialization of a fully synthetic and highly purified human adrenocorticotropic hormone (ACTH) analogs (also termed corticotropin), now designated AMP-110, in the United States and Canada.
accessnewswire.com
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / January 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14th, 2026, at 2:15 pm PT.
fool.com
Amphastar Director Sells 16,679 Shares for $441,800
Floyd Petersen exercised and sold 16,679 shares of Amphastar in November, pocketing more than $441,000. He still retains about $2 million worth of shares.
accessnewswire.com
Amphastar Announces FDA Approval for Teriparatide Injection
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for teriparatide injection, USP 560 mcg/2.24mL (250 mcg/mL) single-patient-use prefilled pen. The FDA determined that Amphastar's teriparatide is bioequivalent and therapeutically equivalent to Eli Lilly's FORTEO®.
defenseworld.net
Capital Fund Management S.A. Takes $931,000 Position in Amphastar Pharmaceuticals, Inc. $AMPH
Capital Fund Management S.A. acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 40,570 shares of the company's stock, valued at approximately $931,000. Capital Fund Management S.A. owned approximately 0.09% of Amphastar Pharmaceuticals
accessnewswire.com
Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / November 24, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be participating in an Analyst-Moderated fireside chat at the 37th Annual Piper Sandler Healthcare Conference on Wednesday, December 3rd, 2025, at 2:00 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.